Smith & Nephew Birmingham HipT :
Smith & Nephew BIRMINGHAM HIP™ (trademark Smith & Nephew) Resurfacing (FDA Approved)
Design of the hip resurfacing started in 1989 and the first implantation was performed in February of 1991. Since 1991 500,000 have been fitted in Europe, the UK, and Australia. 10 May, 2006 US Food and Drug Administration (FDA) approved the BIRMINGHAM HIP™ (trademark Smith & Nephew)
.
Hip Resurfacing conserves more of a patient's bone than a traditional hip replacement, enabling younger, more active patients to undergo hip replacement surgery while preserving all future surgery options, including a primary hip replacement. Hip Resurfacing also offers patients an increased better range of motion with a greatly reduced risk of dislocation. In our experience we have never heard of a hip resurfacing dislocating.AVN and Osteoarthritis sufferers
Some organisations claim that hip resurfacing is an alternative to total hip replacement for patients suffering from abnormalities of the hip, including osteoarthritis. However sufferers with bone disease such as AVN and osteoarthritis should be cautious. Careful assessment of such candidates must take place before deciding whether hip resurfacing would be suitable.
